Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings.
about
A safe lithium mimetic for bipolar disorderDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersConducting clinical research in community mental health settings: Opportunities and challengesContributions of academic laboratories to the discovery and development of chemical biology toolsRemoving obstacles in neuroscience drug discovery: the future path for animal models.Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds.Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans.Tinnitus: network pathophysiology-network pharmacology.Grand challenges and opportunities for molecular psychiatry research: a perspective.The age of anxiety: role of animal models of anxiolytic action in drug discovery.The presynaptic component of the serotonergic system is required for clozapine's efficacy.Neural bases of pharmacological treatment of nicotine dependence - insights from functional brain imaging: a systematic review.NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disordersThe role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Challenges in conducting psychiatry studies in IndiaGenetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice.Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment.Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuseNew therapeutic potential for psychoactive natural products.Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD).Lost in translation. New unexplored avenues for neuropsychopharmacology: epigenetics and microRNAs.The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Looking to the future of research in pediatric anxiety disorders.Neurotransmitter signaling through heterotrimeric G proteins: insights from studies in C. elegans.Breaking the gene barrier in schizophrenia.Experimental models for anxiolytic drug discovery in the era of omes and omics.Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.The role of fMRI in drug development.Mining mouse behavior for patterns predicting psychiatric drug classification.Can we use mice to study schizophrenia?
P2860
Q24600175-6C0F9737-33FA-4C99-AB83-8CED3D7C2A70Q26748728-724706BD-A4B8-490B-8E03-5B895418079DQ27024400-B8098A69-6289-4107-912A-DD8E84FB5999Q28389188-35F57A3B-46BD-40E1-924A-DD0900AF29BBQ28755229-8691DDBA-DA22-4523-9905-FD4C6A715F36Q30369007-28F4F742-CC99-4240-AF13-65F73D9ECA92Q30374052-859BFF3F-8D3C-437A-B6DF-F17812CF8174Q30412371-3DC10E7C-3866-4ED4-BDEA-E3550413B4BAQ30453090-1904193D-AE95-4CF9-969D-74C7CF0735F5Q30462832-82D4C0FF-D335-49AF-983E-E7E4807B0361Q30471071-FE4C82AE-7C48-4000-B493-F40EC6473BB8Q30655273-323ED3BF-1DE6-4823-ADE7-F9C62F812AB8Q34050607-92D824B9-6F4C-4437-B89E-A6DD661CAF06Q34140126-0C8682FF-E3B1-41F6-9CA4-0AB50AAA6F0DQ34227284-DED28630-AFB7-464A-970C-095B3B9789D4Q34870758-B8088795-A7B2-4A2D-82C4-AF91E1B813BEQ34942029-3F44D26D-0931-49C5-9FF1-302808EABD0FQ36441844-B331F0B1-AC16-4F4C-A9F3-AB38BF43F97CQ37188764-2F51CCA5-194B-4C85-9A58-60037E0A6220Q37355904-A6D7B903-39E2-44D9-93CC-AEAF9F29208BQ37660087-EBC7520D-34A5-4E42-BBE3-0FED167D44C4Q37780606-69E379CF-D7AC-4343-A0AC-825E40278A6AQ37945155-1EA4E0A0-6ACF-40BC-B680-528455BEE63DQ38068561-2F9C3D77-9292-492D-AD54-4AD829E6B5C3Q38775856-92C40D1E-CD7E-4A7E-9313-858270F5EA06Q39804940-14B19BE5-403B-4BB0-A073-E8F9FA7A0CF6Q41011634-96D8033B-5429-44D1-BC2B-7522330D3988Q42773108-492FFDDA-C0BF-45DA-94C3-4A1D37734703Q45854291-0AE0FD2F-6FAE-4CA4-9C1A-8F32A05E4664Q47160314-74C8C970-C6C0-484A-9F7D-887DAA23BAA8Q49873690-425F00AF-DF82-4904-8410-2A6DF718213DQ50695065-50665045-B6AD-44CB-8C4D-3B45C458C589Q52710394-F4BED82C-060E-486B-A531-9CF27B1AE128
P2860
Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Opportunities and challenges o ...... stry, and government settings.
@en
Opportunities and challenges o ...... stry, and government settings.
@nl
type
label
Opportunities and challenges o ...... stry, and government settings.
@en
Opportunities and challenges o ...... stry, and government settings.
@nl
prefLabel
Opportunities and challenges o ...... stry, and government settings.
@en
Opportunities and challenges o ...... stry, and government settings.
@nl
P2860
P356
P1476
Opportunities and challenges o ...... stry, and government settings.
@en
P2093
Bryan L Roth
P Jeffrey Conn
P2860
P2888
P304
P356
10.1038/SJ.NPP.1301638
P407
P577
2008-01-23T00:00:00Z
P6179
1008565549